MannKind | MNKD - Interest Expense On Debt


MannKind reported $7.33M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Adma Biologics USD 1.68M 150K Sep/2025
Dynavax Technologies USD 1.64M 2K Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 4.3M 98K Sep/2025
Insmed USD 20.38M 863K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
MannKind USD 7.33M 1.14M Sep/2025
Merck USD 327M 22M Sep/2025
Pfizer USD 652M 2M Sep/2025
Sanofi EUR -25M 252M Dec/2025
Xencor USD 7.66M 578K Sep/2025